Serological markers predict inflammatory bowel disease years before the diagnosis

Schaik, Fiona D.M. van; Oldenburg, Bas; Hart, Andrew; Siersema, Peter D.; Lindgren, Stefan; Grip, Olof; Teucher, Birgit; Kaaks, Rudolf; Bergmann, Manuela M.; Boeing, Heiner; Carbonnel, Franck; Jantchou, P; Boutron‐Ruault, Marie‐Christine; Tjønneland, Anne; Olsen, Anja; Crowe, Francesca L.; Peeters, Petra H.M.; Oijen, Martijn G.H. van; Bueno‐de‐Mesquita, H. Bas

doi:10.1136/gutjnl-2012-302717

Cited by 107 publications

(90 citation statements)

References 34 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although none of them is currently recommended instead of or in addition to ASCA determination, a combination of pANCA, ASCA, anti-CBir1 and anti-OmpC were shown to predict CD and UC in individuals from a low-risk population several years before any clinical sign of the disease [80]. Moreover, it has been suggested that anti-GP2 IgG and IgA serum autoantibodies combined with ASCA are of potential clinical utility in distinguishing CD from UC [36,81], but that they may also be helpful in distinguishing between ileocolonic and colonic CD [35].…”

Section: Serum Markers To Define Type Of Ibdsmentioning

confidence: 99%

Inflammatory bowel diseases: from pathogenesis to laboratory testing

Basso

Zambon²,

Plebani³

2014

Clinical Chemistry and Laboratory Medicine

View full text Add to dashboard Cite

Inflammatory bowel diseases (IBDs), which comprise the two major clinical subtypes, Crohn's disease and ulcerative colitis, incur high morbidity and potential mortality. The present study reviews data on the pathogenesis and diagnosis of IBDs. The pathogenesis depends on complex interactions between susceptibility genes, environmental factors, and innate and adaptive immunity, the understanding of which is crucial to discovering novel laboratory biomarkers. Traditional laboratory tests for the diagnosis, prognosis and assessment of disease activity of IBDs are reported on, and the biochemical properties, preanalytical and analytical aspects and clinical utility of the fecal markers lactoferrin and calprotectin are described. DNA testing and established (ASCA and pANCA) and emerging (ACCA, ALCA, AMCA, OmpC) serum markers are described; a further aspect to be addressed is the clinical use of pharmacogenetics for the treatment of IBDs.

show abstract

Section: Serum Markers To Define Type Of Ibdsmentioning

confidence: 99%

Inflammatory bowel diseases: from pathogenesis to laboratory testing

Basso

Zambon²,

Plebani³

2014

Clinical Chemistry and Laboratory Medicine

View full text Add to dashboard Cite

show abstract

“…[37][38][39][40] These biomarkers predict and are qualitatively and quantitatively associated with an aggressive and complicated course of Crohn's disease, including stricturing and/or penetrating phenotype, both in adult and paediatric patients. 13 However, a recent study showed that none of the anti-glycan antibodies ASCA, AMCA, ACCA, ALCA, anti-L and anti-C correlates with disease phenotype.…”

Section: Antimicrobial Antibodiesmentioning

confidence: 99%

Biomarkers of intestinal fibrosis – one step towards clinical trials for stricturing inflammatory bowel disease

Giuffrida

Pinzani

Corazza

et al. 2016

United European Gastroenterology Journal

View full text Add to dashboard Cite

Intestinal fibrosis, caused by an excessive deposition of extracellular matrix components, and subsequent stricture development are a common complication of inflammatory bowel disease. However, currently there are no biomarkers which reliably predict the risk of developing intestinal strictures or identify early stages of fibrosis prior to clinical symptoms. Candidate biomarkers of intestinal fibrosis, including gene variants (i.e. nucleotide-binding oligomerization domain-2 gene), serum microRNAs (miR-19, miR-29), serum extracellular matrix proteins (i.e. collagen, fibronectin) or enzymes (i.e. tissue inhibitor of matrix metalloproteinase-1), serum growth factors (i.e. basic fibroblast growth factor, YKL-40), serum anti-microbial antibodies (i.e. anti-Saccharomyces cerevisiae) and circulating cells (i.e. fibrocytes) have shown conflicting results on relatively heterogeneous patients' cohorts, and none of them was proven to be strictly specific for fibrostenosis, but rather predictive of a disease disabling course. In this review we critically reassess the diagnostic and prognostic value of serum biomarkers of intestinal fibrosis in inflammatory bowel disease.

show abstract

“…In light of these considerations, it would seem advantageous to have multiplex tests (microarray, blot) using predefined profiles [7], in which diverse markers are tested simultaneously with the objective of providing a complete report, useful either for diagnostic orientation (Crohn's disease, ulcerative colitis or celiac disease) or for determining risk stratification. Multiple pathology-oriented antibody profiles might, in addition, demonstrate their usefulness in predicting IBD onset in the pre-diagnostic phase, as already demonstrated for ASCA [8], and very recently for anti-CBir1 and anti-OmpC [9] that have been detectable in the sera of apparently healthy subjects, on average 3-4 years before the disease became manifest, thus introducing a window of opportunity for early intervention.…”

mentioning

confidence: 99%